This trial is evaluating whether Ramucirumab will improve 2 primary outcomes in patients with Adenocarcinoma. Measurement will happen over the course of Last randomized patient on study at least 16 weeks.
This trial requires 450 total participants across 4 different treatment groups
This trial involves 4 different treatments. Ramucirumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
"Most gastric cancers will recur in the liver or the lungs. Most gastric cancers are in situ at the time of diagnosing, thus curing and achieving optimal organ preservation cannot be achieved." - Anonymous Online Contributor
"There will be more than 40,000 new cases of stomach cancer in the USA in 2019, and more than 21,000 people will die from stomach cancer that year." - Anonymous Online Contributor
"One third of the patients were smokers. More than 85% of the patients who developed stomach cancer in this study were older than 60 years of age. The patients with stomach cancer had large volume of alcohol consumption, Helicobacter pylori infection, and NSAID consuming." - Anonymous Online Contributor
"Gastric cancer causes many symptoms, which depend on the site and the aggressiveness of the tumor. These symptoms are classified into local and distant metastases. Other causes of cancer pain include other metastatic cancer, congestive heart failure, and chronic kidney disease. These signs can also occur in the absence of a true primary tumor." - Anonymous Online Contributor
"Treatment options are very variable between nations (e.g., surgery versus radiation versus chemoradiation), but overall this treatment paradigm involves chemotherapy, radiation therapy, or surgery followed by adjuvant treatment with gemcitabine in cases of gastric cancer." - Anonymous Online Contributor
"Cancer of stomach is a devastating disease with heavy morbidity and deaths in the developing world, where [gastric cancer](https://www.withpower.com/clinical-trials/gastric-cancer)s are the most common type of stomach cancer." - Anonymous Online Contributor
"There is much clinical support for alx148 based on results from multiple clinical trials. The development of alx148 is ongoing and additional therapeutic properties of alx148 are being evaluated including a new indication in the treatment of acute heart failure based on alx148's activity and positive results from the ALX-037 pivotal study." - Anonymous Online Contributor
"The main common side effect is swelling of the arm or leg. Other common side effects include itchiness, fever, vomiting, and headache. People who have taken evorpacept for a longer amount of time had a higher frequency of nausea." - Anonymous Online Contributor
"Results showed, from one of the first safety trials that included patients who have undergone malignancy treatment, that Alx148 is well tolerated for patients with a variety of prior malignancy. Alx148 provided benefit for patients with recurrent or second primary cancers, especially if used in conjunction with corticosteroids. In this sense, Alx148 is a novel option to alleviate some of the troubling symptoms of cancer survivors. It achieves these benefits without causing toxicity at doses that cause few side effects, and it achieves effectiveness without compromising quality of life." - Anonymous Online Contributor
"No improvement in survival time of patients with metastatic cancer was measured by evorpacept. In fact, the median survival time was 6.9 months in patients given placebo compared to 6.3 months in patients taking evorpacept." - Anonymous Online Contributor
"ALX148 had no influence on any of the measured EORTC QL assessments for patients with cancer of the stomach. The study has shown the difficulty in determining relevant, meaningful changes in QL that will aid health professionals when evaluating therapies." - Anonymous Online Contributor
"In comparison to other types of cancers of the gastrointestinal tract (e.g., colon cancer, gastric cancer), cancer of the stomach is less common and often metastasizing. Most common sites of distant metastasis in stomach cancer is to lymph node. Survival time is generally short, except for the case of the early-stage N2-3 gastric cancer." - Anonymous Online Contributor